Takeda Pharmaceutical Company Limited

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Takeda Pharmaceutical Company Limited
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Headquarters city
Tokyo
Headquarters country
Japan
Ticker symbol
TAK
Primary stock exchange
NYSE

Identifiers

SEC CIK
0001395064

Board of directors

Follow this board

Chief executives

Julie So-Young Kim · President and CEO
Dates unknown
Christophe Pierre Weber · President and CEO
Since March 2026

Board connections

9 of this board's directors also sit on 25 other boards.

Network of Takeda Pharmaceutical Company Limited's board connections Boston Scientific Corporation Boston Scientific Corp... Agios Pharmaceuticals Inc. Agios Pharmaceuticals... Beam Therapeutics Inc. Beam Therapeutics Inc. BioMarin Pharmaceutical Inc. BioMarin Pharmaceutica... Blaize Holdings Inc. Blaize Holdings Inc. Corvus Pharmaceuticals Inc. Corvus Pharmaceuticals... GoodRx Holdings Inc. GoodRx Holdings Inc. Guardant Health Inc. Guardant Health Inc. HA Sustainable Infrastructure Capital Inc. HA Sustainable Infrast... HP Inc. HP Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Humana Inc. Humana Inc. KLA Corporation KLA Corporation Kardigan Inc. Kardigan Inc. Kymera Therapeutics Inc. Kymera Therapeutics In... Kyverna Therapeutics Inc. Kyverna Therapeutics I... Bruce D. Broussard Bruce D. Broussard Christophe Pierre Weber Christophe Pierre We... Emiko Higashi Emiko Higashi Ian T. Clark Ian T. Clark John Maraganore John Maraganore Kimberly A. Reed Kimberly A. Reed Steven Gillis Steven Gillis Yoshiaki Fujimori Yoshiaki Fujimori Takeda Pharmaceutical Comp...
Shared director Other board Same sector +9 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$13,088,587
20 sales by 13 insiders
Date Insider Transaction Shares Price Value
Sep 14, 2026 Duprey Lauren Rusckowski Officer (Chief Transformation Officer) Open-market sale −34,535 $18.54 $640,279
Sep 2, 2026 Andrew Stewart Plump Director, Officer (President, R&D) Open-market sale −116,191 $18.49 $2,148,372
Aug 19, 2026 Andrew Stewart Plump Director, Officer (President, R&D) Open-market sale −19,651 $18.49 $363,347
Aug 18, 2026 Greenway Nicola Deidre Petal Officer (Chief Human Resources Officer) Open-market sale −12,980 $18.11 $235,118
Aug 11, 2026 Shannon Elaine Mary Officer (Pres., Global Supply & Quality) Open-market sale −20,363 $17.55 $357,371
Aug 10, 2026 Teresa Marie Bitetti Officer (President, OBU) Open-market sale −50,012 $17.10 $855,205
Aug 10, 2026 Duprey Lauren Rusckowski Officer (Chief Transformation Officer) Open-market sale −47,586 $17.10 $813,721
Aug 10, 2026 Farajallah Awny Samaan Botros Officer (Chief Medical Officer) Open-market sale −14,006 $17.10 $239,503
Aug 10, 2026 Furney Natalie Anne Marie Officer (Global General Counsel) Open-market sale −30,868 $17.10 $527,843
Aug 10, 2026 Greenway Nicola Deidre Petal Officer (Chief Human Resources Officer) Open-market sale −975 $17.50 $17,063
Aug 10, 2026 Greenway Nicola Deidre Petal Officer (Chief Human Resources Officer) Open-market sale −6,774 $17.10 $115,835
Aug 10, 2026 Ibrahim Ramy Riad Ahmed Officer (President, PDT BU) Open-market sale −7,277 $17.10 $124,437
Aug 10, 2026 Julie So-Young Kim Director, Officer (President and CEO) Open-market sale −89,090 $17.10 $1,523,439
Aug 10, 2026 Pacheco Rhonda Janice Officer (President, U.S. Business Unit) Open-market sale −16,901 $17.10 $289,007
Aug 10, 2026 Pignagnoli Agosti Marcello Officer (Head, Strat. & Port. Dev) Open-market sale −22,957 $17.10 $392,565

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.